Showing results (31-40 of 2,507) with videos related to

Sort By:
Pageof 251
Clinical Lymphoma, Myeloma & Leukemia|April 15, 2022
Presentation and Impact of Double and Triple hit Cytogenetics in Patients With Multiple Myeloma in the Real WorldCharanpreet Singh, Vandana Panakkal, Sreejesh Sreedharanunni, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 17, 2010
The sarcoid-lymphoma syndromeTrishna Goswami, Shahzad Siddique, Phillip Cohen, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 17, 2010
Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcomePier Luigi Zinzani, Letizia Gandolfi, Vittorio Stefoni, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 17, 2010
Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosisSameer A Parikh, Hagop Kantarjian, Aaron Schimmer, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 30, 2010
Fcγ receptor polymorphisms and clinical efficacy of rituximab in non-Hodgkin lymphoma and chronic lymphocytic leukemiaYun Zhuang, Wei Xu, Yunfeng Shen, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 1, 2010
Risk-adapted approaches to therapy for high-risk acute promyelocytic leukemiaAarati Ranganathan, Bayard L Powell
Clinical Lymphoma, Myeloma & Leukemia|December 16, 2010
Outcome of patients with IgD and IgM multiple myeloma undergoing autologous hematopoietic stem cell transplantation: a retrospective CIBMTR studyDonna E Reece, David H Vesole, Smriti Shrestha, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 16, 2010
A Phase II trial of gemcitabine and mitoxantrone for patients with acute myeloid leukemia in first relapseAnjali S Advani, Mazyar Shadman, Francis Ali-Osman, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2011
Prognostic relevance of immunohistochemical subclassification of diffuse large B-cell lymphoma in two prospective phase III clinical trialsNazik Rayman, King H Lam, Bronno van der Holt, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2011
Efficacy and safety of pegylated liposomal Doxorubicin in combination with bortezomib for multiple myeloma: effects of adverse prognostic factors on outcomeJoan Bladé, Pieter Sonneveld, Jesús F San Miguel, et al.
Pageof 251